Haiyi Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Haiyi Guo has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chao Lei
Department of Surgery, Division of Immunotherapy, University of Louisville, Louisville, USA
1 shared publication - Dingbo Song
Department of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang 453003, China
1 shared publication - Fangqi Hu
Department of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang 453003, China
1 shared publication - Jinyuan Li
Department of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang 453003, China
1 shared publication - Mengyao Zhang
Department of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang 453003, China
1 shared publication - Qiuhan Liang
Department of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang 453003, China
1 shared publication
Latest Publications
- Open Access
- 24 August 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1226
Intestinal Fucosylation: A Key Regulatory Hub in Homeostasis and Disease Pathogenesis
Inflammatory bowel disease (IBD) and colorectal cancer (CRC) are heterogeneous intestinal disorders that pose significant threats to human health and share common pathological features, including intestinal mucosal barrier disruption and gut microbiota dysbiosis, in which fucosylation acts as a critical regulatory mediator. Fucosylation is a highly conserved post-translational glycosylation modification involving the enzymatic transfer of fucose residues to glycoproteins and glycolipids. This tightly regulated process plays essential roles in maintaining intestinal homeostasis, mediating host–microbiota interactions and regulating immune responses. This review adopts a physiology-to-pathology framework, delineating fucosylation’s operational principles in healthy intestines and its dysregulation in IBD and CRC. It summarizes the spatial distribution of fucosylation, its regulatory mechanisms, and its roles in disease pathogenesis, and also discusses its potential as a diagnostic biomarker and therapeutic target. Finally, this review highlights future research directions to bridge mechanistic insights with clinical translation, emphasizing the promise of fucosylation in the precision diagnosis and treatment of intestinal disorders.
- 24 August 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1226
Open AccessIntestinal Fucosylation: A Key Regulatory Hub in Homeostasis and Disease Pathogenesis
Inflammatory bowel disease (IBD) and colorectal cancer (CRC) are heterogeneous intestinal disorders that pose significant threats to human health and share common pathological features, including intestinal mucosal barrier disruption and gut microbiota dysbiosis, in which fucosylation acts as a critical regulatory mediator. Fucosylation is a highly conserved post-translational glycosylation modification involving the enzymatic transfer of fucose residues to glycoproteins and glycolipids. This tightly regulated process plays essential roles in maintaining intestinal homeostasis, mediating host–microbiota interactions and regulating immune responses. This review adopts a physiology-to-pathology framework, delineating fucosylation’s operational principles in healthy intestines and its dysregulation in IBD and CRC. It summarizes the spatial distribution of fucosylation, its regulatory mechanisms, and its roles in disease pathogenesis, and also discusses its potential as a diagnostic biomarker and therapeutic target. Finally, this review highlights future research directions to bridge mechanistic insights with clinical translation, emphasizing the promise of fucosylation in the precision diagnosis and treatment of intestinal disorders.